Panacea will handle product development and commercial manufacturing, and the venture company will be responsible for clinical development and regulatory submissions worldwide. Panacea and Refana will handle sales and distribution of the vaccine in their respective territories.

Refana aims to manufacture over 500 million doses of the COVID-19 vaccine candidate, with over 40 million doses expected to be available for delivery in early 2021.

Preclinical innovations can speed COVID-19 drug development
Preclinical testing for drug candidates has remained largely unchanged, despite numerous innovations in cell culture techniques. Researchers discussed...

Partnership aims to accelerate COVID-19 vaccine
The development, manufacture, and distribution of a COVID-19 vaccine candidate is the goal of a new partnership that includes the Coalition for Epidemic...

Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against...

Gates Foundation directs $1.6B to Gavi, the Vaccine Alliance
The Bill and Melinda Gates Foundation announced a five-year, $1.6 billion U.S. commitment to Gavi, the Vaccine Alliance, to deliver vaccines to developing...

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...